A Study of JNJ-64300535 in Healthy Participants

Phase 1 Completed 14 enrolled Janssen Research & Development, LLC

NaSingle-groupOpen-labelOther

Summary

The purpose of this study is to evaluate the cellular immunogenicity of 3 monthly electroporation-mediated intramuscular (IM) injections of JNJ-64300535 in healthy participants.

Timeline

Start: 2021-02-03
Primary completion: 2021-12-07
Completion: 2021-12-07

Publications

Verheijden S, Conceicao-Neto N, Bourgeois S, Vandamme C, Troyer E, Kanoulas E, Maeyer D, Crabbe M, Makariadou E, Slaets L, Fevery B, Remoortere PV, Biermer M, Kennedy PTF, De Creus A. Safety, immunogenicity, and baseline immune correlates of vaccine JNJ-0535 in participants with or without CHB. NPJ Vaccines. 2026 Feb 5;11(1):45. doi: 10.1038/s41541-025-01364-x.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	JNJ-64300535	Vaccine	—	Intramuscular

Indications

No indication recorded.